Byrne Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Byrne Asset Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5	Hold	4	–	–	﹤0.01%	619
2026 Q2	$4	Hold	4	–	–	﹤0.01%	588
2026 Q1	$7	Hold	4	–	–	﹤0.01%	562
2025 Q4	$7	Buy	+4	New	+$9	﹤0.01%	556

Other funds holding INO

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Byrne Asset Management's INO Position: Q3 2026 in Review

Byrne Asset Management held its Inovio Pharmaceuticals (INO) position steady in Q3 2026 at 4 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #619.

Byrne Asset Management first reported a position in INO in Q4 2025 and has held it in 4 quarters since. The position peaked at $7 in Q1 2026. 5 funds tracked by Wall St. Rank hold INO as of Q3 2026.

Byrne Asset Management held 4 shares of Inovio Pharmaceuticals worth $5 as of Q3 2026.
Byrne Asset Management left its Inovio Pharmaceuticals share count unchanged in Q3 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Byrne Asset Management's portfolio in Q3 2026, its #619 holding.
Byrne Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
Byrne Asset Management's Inovio Pharmaceuticals position peaked at $7 in Q1 2026.
5 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2026.

Based on Byrne Asset Management's 13F filing for Q3 2026, filed 6 Oct 2026.